Latest news with #AndroidPro14
Time of India
2 days ago
- Health
- Time of India
Top US doctor warns of common habits that are silently harming the gut
Harvard-trained gastroenterologist Dr. Saurabh Sethi highlights common habits silently harming gut health. Eating too fast triggers bloating, while artificial sweeteners disrupt the gut microbiome. Skipping meals leads to insulin spikes, and sleep deprivation weakens the gut lining. Excessive painkiller use damages the digestive tract. Dr. At a time when we are constantly bombarded by food vloggers glorifying midnight junk food cravings and online wellness influencers pushing the so-called gut-detox drinks, a Harvard doctor is urging people to hit pause and pay closer attention to their everyday habits. Dr. Saurabh Sethi, a California-based gastroenterologist trained at Harvard and Stanford, has shared a list of common habits that are silently destroying gut health. The gut doctor said that these common habits could be wreaking havoc on your digestive system. Let's take a look. Eating too fast Life has gotten so busy that many people barely take the time to sit down and enjoy a meal. Rushing through meals has become more common. Though many won't understand the danger behind it, Dr. Sethi warned that this habit can affect gut health. He noted that eating too fast can trigger bloating and acid reflux. When you eat too quickly, you often fail to chew your food properly. This forces the stomach to work harder to break down food, which can lead to discomfort and strain on the digestive system. The fix? Take your time. Give yourself at least 20 minutes per meal to improve digestion and reduce symptoms. Turning to artificial sweeteners Dr. Sethi has warned against using too many artificial sweeteners. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Нов таблет с Android Pro 14 Murreice Купете сега Undo Artificial sweeteners like sucralose and aspartame, found in many diet sodas and sugar-free products, may seem harmless, but can disrupt gut health. These sweeteners can alter the gut microbiome and potentially cause inflammation and digestive issues. Limiting artificial sweeteners and opting for natural alternatives, such as honey, if your health condition permits it, would be a better option. Skipping meals and later overeating Irregular eating habits can cause more harm than you think. Amidst work deadlines and personal duties, people tend to skip meals throughout the day, and then overeat at night. The gastroenterologist has warned that this habit may lead to insulin spikes and also put undue stress on the digestive system. This irregular pattern of eating can also lead to weight gain and gut inflammation over time. Focus on eating balanced meals at consistent times, do not starve your body, or overwhelm it with excess food. Balance is the key. Not getting enough sleep (Pic courtesy: iStock) Among the many things people tend to sacrifice to squeeze in their personal or career goals is their sleep. However, sleep deprivation can wreak havoc on your health, especially the gut. A restful sleep provides the gut time to rest for the next day. Chronic sleep deprivation disrupts this process. Lack of sleep can weaken the gut lining and increase the risk of issues like leaky gut syndrome. Remember, sleep is non-negotiable. Aim for at least seven to eight hours of quality sleep nightly. Excess use of painkillers Most of us have the habit of popping painkillers every now and then. But it may be doing more harm than good. Dr. Sethi has stressed that excessive use of NSAIDs (Nonsteroidal Anti-inflammatory Drugs) can damage the gut lining. NSAIDs like ibuprofen, aspirin, naproxen, and diclofenac can cause irritation, ulcers, or even bleeding in the digestive tract over time. Remember, NSAIDs are helpful but should be used sparingly. Brandon Gill's 'Uncivilised' Jab at Mamdani Sparks Cultural Backlash Online
Time of India
3 days ago
- Business
- Time of India
South American bloc looks to Asia, Europe in face of Trump trade war
South America's Mercosur bloc sought Thursday to expand its markets in the face of US President Donald Trump 's global trade war, with Brazil calling for closer ties with dynamic Asian economies. "It's time for Mercosur to look toward Asia," President Luiz Inacio Lula da Silva said, extolling the potential benefits of deeper relations with Japan, China, South Korea, India, Vietnam and Indonesia. In a reflection of regional tensions, however, Argentina's President Javier Milei threatened to go it alone if necessary to secure a free trade deal with the United States. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Нов таблет с Android Pro 14 Murreice Купете сега Undo "We will embark on the path of freedom, and we will do so together or alone because Argentina cannot wait," Milei warned, calling for "more freedom" to negotiate. The libertarian leader, a huge fan of Trump, has made no secret of his disdain for Lula, referring to him in the past as "corrupt" and a "Communist." Live Events Lula, on his first trip to Argentina since Milei took office in December 2023, had no bilateral talks with the self-declared "anarcho-capitalist." The veteran Brazilian leftist, who took over Mercosur's rotating presidency from his Argentine counterpart, has accused Milei of talking "nonsense." Lula said that under his leadership, Mercosur would aim to "strengthen inter-bloc trade with external partners" and to implement a landmark trade agreement with the European Union. Brussels in December struck a deal with Mercosur's founding members -- Argentina, Brazil, Paraguay and Uruguay -- to create a free trade zone of around 700 million consumers. The agreement has been 25 years in the making, but still needs to be ratified by EU member states. It has faced stiff opposition from France, where farmers worry about being undercut by less-regulated Latin American peers. Climate change on agenda Uruguayan President Yamandu Orsi said that it was now "time to resume negotiations with key partners such as South Korea and Canada." Uruguay has for decades sought a relaxation of the bloc's rules, which prevent agreements with other countries without the consent of all partners. Climate change, the energy transition, combating organized crime and promoting technological development would be Mercosur's main objectives during the next six months, Lula said. Steps were discussed to make progress on trade agreements with the United Arab Emirates and Canada, as well as update accords with Colombia, Ecuador, Panama and the Dominican Republic, and to advance regional gas integration. On Wednesday, Mercosur foreign ministers announced a free trade agreement with the European Free Trade Association, made up of non-EU members Iceland, Liechtenstein, Norway and Switzerland. Adding to the tense atmosphere surrounding the summit, Lula took the time to visit his ally Cristina Kirchner, the former Argentine president who is under house arrest. Lula, who was granted permission by a court to see Kirchner, spent almost an hour at her apartment in Buenos Aires. He found her "in good health, strong and determined to fight," he said on social media platform X. "In addition to expressing my solidarity with her for everything she has been through, I wished her all the strength she needed to continue fighting, with the same determination that has characterized her career," he wrote. Kirchner hailed the visit as "much more than a personal gesture: it was a political act of solidarity," in her own message on X. Kirchner, the standard-bearer of the Argentine left for over two decades, was convicted of "fraudulent administration" while president between 2007 and 2015. The 72-year-old, who says her trial was an attempt to silence her criticism of the right, began a six-year sentence last month after losing a Supreme Court appeal.
Time of India
4 days ago
- Business
- Time of India
Nykaa block deal: Founders offload shares worth Rs 1,200 crore; stock falls 4.5%
Representative image Shares of FSN E-Commerce Ventures, the parent firm of beauty and fashion retailer Nykaa, fell by up to 4.5 per cent on Thursday, hitting a low of Rs 202.25 on the BSE , after around six crore shares exchanged hands in a large block deal. According to ET, this transaction accounted for roughly 2.3 per cent of the company's total equity. The decline followed reports that early investors Harindarpal Singh Banga and Indra Banga were planning to offload part of their holdings through a secondary sale valued at nearly Rs 1,200 crore. Term sheets issued ahead of the transaction indicated that around 60 million shares, or 2.1 per cent of Nykaa's equity, would be sold at a floor price of Rs 200 per share, reflecting a discount of approximately 5.5 per cent to the stock's closing price of Rs 211.59 on July 2. The deal, entirely a secondary transaction, does not involve issuing new shares, meaning the proceeds will go directly to the selling shareholders. According to ET, global investment banks Goldman Sachs (India) Securities and JP Morgan India are overseeing the sale. The trade is scheduled for execution on July 3, with settlement due the following day. A 45-day lock-in period has been placed on the sellers and their affiliates, barring any further share sales during this time. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Нов таблет с Android Pro 14 Murreice Купете сега Undo Retail investors will not be allowed to participate, and distribution in the US and Canada is limited to institutional investors under respective local regulations. Eligible buyers must also sign an investor representation letter as part of the process. The final share price will be determined through a screen-based mechanism depending on investor demand. The order books are expected to close by 7:30 am on the day of the deal, and foreign portfolio investors (FPIs) may take part, provided there is regulatory space under Indian law. This stake sale comes at a time when Nykaa is witnessing renewed interest from institutional investors amid signs of a gradual stock recovery. It also reflects a strategic monetisation by key shareholders as the company pushes to improve profitability. As per PTI, Nykaa is targeting a break-even for its loss-making fashion segment by FY26, driven by improved marketing efficiency, higher own-brand sales, and overhead leverage. The vertical reported a negative EBITDA margin of 8.3 per cent in FY25, despite generating Rs 3,800 crore in GMV. In FY25, Nykaa's profit more than doubled to Rs 66.08 crore from Rs 32.26 crore the previous year. Revenue rose by 24.4 per cent to Rs 7,949.82 crore. The customer base also grew by 28 per cent year-on-year to over 42 million, while its total GMV reached Rs 15,604 crore. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Time of India
24-06-2025
- Health
- Time of India
Weight-loss drug Wegovy starts at ₹17,345 in India
Mumbai: Wegovy (semaglutide), the popular weight-loss drug from Danish drug maker Novo Nordisk , is priced between '17,345 and '26,015 across dosages in India. The company announced at its launch that the easy-to-administer once-a-weekly pen-filled injectable will have the advantage of convenient dosing. The drug will be available in five dosing strengths (0.25, 0.5, 1, 1.7 and 2.4 mg) and will be prescribed for long-term chronic weight management and reduction in risk of major adverse cardiovascular events (MACE). Vikrant Shrotriya, MD, Novo Nordisk India, said obesity is a chronic disease and a national epidemic. "Wegovy is a transformative therapeutic solution with the convenience of a world-class, state-of-the-art pen device," he noted. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Нов таблет с Android Pro 14 Murreice Купете сега Undo Ambrish Mithal, chairman and head, endocrinology and diabetes, Max Healthcare , said although the price of Wegovy is not within the reach of the Indian masses, the potential for the drug is huge. Live Events Over time, he said, the cardiovascular benefit of Wegovy 2.4 mg is an important addition to the weight loss benefits. It is clinically proven to reduce cardiac events by 20%, both in people suffering from overweight/obesity with pre-existing heart disease. The drug can be prescribed for patients with BMI over 30 and those with BMI above 27 and pre-existing co-morbidities. Bariatric surgeon Mufazzal Lakdawala told ET that weight-loss drugs are proving to be the game-changers and they have just unlocked the potential for obese patients. He said the new age weight loss drugs could potentially complement bariatric surgery for patients beyond BMI of 45-50 as a weight-loss option. Compared to Wegovy, Mounjaro's 2.5 mg and 5 mg vials, which are also given on a weekly basis, are priced at '14,000 to '17,500 for a month's dose.
